Palbocib 125 mg Palbociclib Capsules (1 bottle / 21 caps)

At a Glance

Generic Name: Palbociclib

Brand Name: Palbocib 125 mg

Strength & Pack Size: 125 mg capsules, 1 bottle / 21 capsules

Dosage Form & Route: Hard gelatin capsules for oral use

Therapeutic Class: CDK4/6 inhibitor targeted therapy

Primary Indications: Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults, in combination with endocrine therapy as per local label

Typical Patient Profile: Adults with HR-positive, HER2-negative breast cancer where CDK4/6 inhibition is appropriate based on specialist assessment

Mode of Action: Selectively inhibits cyclin-dependent kinases 4 and 6 to arrest cell-cycle progression in tumour cells

Key Benefits: Improved progression-free outcomes when combined with endocrine therapy in eligible patients, with an oral, at-home dosing schedule

Precautions: Requires regular blood count monitoring, assessment for infections, liver tests and effective contraception; use only under oncology supervision

Storage: Store in the original bottle below the temperature stated on the pack, tightly closed and protected from moisture, out of the reach of children

Product Description

Palbocib 125 mg contains palbociclib, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with endocrine therapy for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Rather than acting as classic cytotoxic chemotherapy, palbociclib is a targeted therapy designed to disrupt key cell-cycle regulators that drive uncontrolled proliferation in HR-positive breast cancer cells.

Each bottle of Palbocib 125 mg palbociclib capsules supplied by Generic Meds Mart contains 21 capsules, reflecting a standard 21-day “on treatment” period in a typical 28-day cycle when the medicine is used according to its approved schedule. The 125 mg strength is frequently chosen as the starting dose for many adults, with dose adjustments made by the treating oncologist if neutropenia or other side effects arise. Palbocib 125 mg is almost always prescribed alongside endocrine therapy such as an aromatase inhibitor or fulvestrant, forming a combination regimen that targets both hormonal signalling and cell-cycle control.

Generic Meds Mart sources Palbocib 125 mg palbociclib capsules only from licensed manufacturers and authorised distributors. Each bottle and outer carton displays the brand name, strength, generic name, batch number and expiry date so that oncology pharmacies can verify the medicine before dispensing. Parcels are shipped in neutral outer packaging without visible references to breast cancer or targeted therapy, supporting patient privacy while maintaining full traceability through invoices and batch documentation. Our role is limited to access and logistics; all treatment decisions remain with your oncology team.

Key Uses

Palbocib 125 mg palbociclib capsules are used as part of systemic therapy for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults, according to local prescribing information and guidelines. Typical uses include:

• Use with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women and other eligible adults with HR-positive, HER2-negative advanced or metastatic breast cancer.
• Use with fulvestrant in patients whose disease has progressed after prior endocrine therapy, where a CDK4/6 inhibitor remains appropriate.
• Use in carefully selected patient groups where dual targeting of hormone signalling and CDK4/6-mediated cell-cycle pathways is expected to improve disease control compared with endocrine therapy alone.

Exact positioning of Palbocib 125 mg within the treatment pathway depends on prior therapies, menopausal status, comorbidities, tumour burden and local practice. The choice of partner endocrine therapy and sequencing relative to other systemic agents is always determined by a specialist.

How Palbociclib Works in Chemotherapy

Palbociclib, the active ingredient in Palbocib 125 mg, is a selective inhibitor of cyclin-dependent kinases 4 and 6. These kinases form complexes with D-type cyclins and play a central role in regulating transition from the G1 to S phase of the cell cycle, a checkpoint that determines whether a cell proceeds to DNA synthesis and division. In hormone receptor-positive breast cancer, CDK4/6 activity is often upregulated, contributing to uncontrolled proliferation.

By inhibiting CDK4 and CDK6, palbociclib reduces phosphorylation of the retinoblastoma (Rb) protein, a gatekeeper of G1-to-S progression. Reduced Rb phosphorylation keeps the cell-cycle checkpoint engaged, leading to G1 arrest and limiting proliferation of sensitive tumour cells. When combined with endocrine therapy that reduces or blocks estrogen-driven signalling, palbociclib helps slow tumour growth, delay progression and extend the duration of response in many patients with HR-positive, HER2-negative metastatic disease.

Dosage & Administration

Palbocib 125 mg palbociclib capsules must only be prescribed and monitored by oncologists experienced in treating advanced breast cancer with CDK4/6 inhibitors. The commonly used schedule is 125 mg taken once daily for 21 consecutive days, followed by 7 days off treatment, forming a 28-day cycle. Palbociclib is given alongside a companion endocrine therapy, which may be taken continuously or on its own schedule depending on the product used.

Capsules should be swallowed whole with water and should not be chewed, opened or crushed. Patients are usually advised to take Palbocib 125 mg at approximately the same time each day and to follow the instructions in the patient leaflet regarding food. If a dose is missed or vomited, patients should follow their oncologist’s or pharmacist’s advice rather than doubling the next dose. Before each cycle and at defined points during therapy, complete blood counts and other tests are performed. Dose reductions or interruptions may be required if neutropenia, thrombocytopenia or other toxicities reach predefined thresholds.

Precautions

Before starting Palbocib 125 mg, the oncology team will review the patient’s prior treatments, blood counts, liver function, concomitant medicines and infection risk. Palbociclib can cause clinically significant neutropenia, increasing susceptibility to infections, so patients should be educated about promptly reporting fever or signs of illness. Strong inhibitors or inducers of CYP3A may alter palbociclib exposure and often need to be avoided or managed carefully.

Effective contraception is strongly recommended for people of childbearing potential during palbociclib therapy and for a period after stopping, as palbociclib may harm a developing fetus. Breastfeeding is generally not recommended while taking Palbocib 125 mg. Patients should inform their care team about any planned procedures, new medicines or herbal supplements, and should never adjust their palbociclib dose without medical advice.

Palbociclib Side Effects

Common side effects

Common palbociclib side effects in patients taking Palbocib 125 mg include neutropenia and leukopenia, often detected on routine blood tests, as well as fatigue, nausea, decreased appetite, diarrhoea, constipation, mild stomatitis or mouth sores, hair thinning, low-grade infections, headache and mild elevations in liver enzymes. Many of these effects are manageable with supportive care, cycle-by-cycle monitoring and dose modifications. Patients are routinely counselled on infection precautions and when to seek urgent care.

Serious side effects

Serious palbociclib adverse effects require urgent medical attention and may include febrile neutropenia or severe infections, severe or persistent neutropenia, significant thrombocytopenia with bleeding, pronounced liver enzyme elevations, interstitial lung disease or pneumonitis, and very rare severe hypersensitivity reactions. Warning signs include high fever, chills, shortness of breath, persistent cough, chest pain, unexplained bruising or bleeding, dark urine, yellowing of the skin or eyes or severe fatigue and weakness. If any of these occur while using Palbocib 125 mg palbociclib capsules, emergency medical review is essential and treatment may need to be interrupted or adjusted.

Storage

Palbocib 125 mg capsules should be stored in the original bottle with the cap tightly closed, at or below the temperature stated on the carton, and protected from moisture. The bottle should be kept out of the sight and reach of children and should not be stored in the bathroom or other humid environments. Capsules must not be used after the expiry date on the label, and any unused or expired palbociclib should be returned to a pharmacy or disposed of via an approved medicines take-back programme, not in household waste or wastewater.

Why Buy from Generic Meds Mart

Generic Meds Mart is dedicated to improving access to targeted oncology medicines such as Palbocib 125 mg palbociclib capsules for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. We work only with licensed manufacturers and authorised exporters that follow recognised quality standards and maintain documented batch traceability. Each bottle is supplied in sealed original packaging so that treating oncologists and pharmacy teams can confirm the product name, strength, batch number and expiry before advising patients.

All orders are processed in USD through secure checkout, and shipments are packed in discreet, neutral outer packaging that does not mention breast cancer or targeted therapy. Where available, trackable shipping options help patients and clinics coordinate refills so that palbociclib cycles can continue without unnecessary interruptions. Our role is limited to logistics and access; decisions about when to start, adjust or stop Palbocib 125 mg therapy remain entirely with your oncology specialists.

Order Now

Before ordering Palbocib 125 mg palbociclib capsules from Generic Meds Mart, you should have a clear treatment plan from your oncologist specifying that a CDK4/6 inhibitor combined with endocrine therapy is appropriate for your breast cancer and detailing the intended dose, cycle structure and monitoring schedule. Your team will explain the goals of therapy, expected time course of response, possible side effects and when to contact the clinic urgently.

Once this plan is in place, you can select Palbocib 125 mg (1 bottle / 21 caps), choose the number of bottles needed for your prescribed cycles and complete secure checkout in USD. Medicines will be dispatched in discreet packaging with documentation including product and batch details for your records and for your oncology pharmacy. You should never start, stop or change palbociclib dosing without specialist guidance, and any concerning symptom during treatment should be reported promptly so your team can adjust your care safely.

FAQ about Palbocib (Palbociclib)

Q1: What is Palbocib 125 mg used for?
Palbocib 125 mg contains palbociclib, a CDK4/6 inhibitor used in combination with endocrine therapy for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults, according to local prescribing information and oncology guidelines.

Q2: Is Palbocib 125 mg a form of chemotherapy?
Palbocib 125 mg is considered targeted therapy rather than traditional cytotoxic chemotherapy. It interferes with CDK4/6-mediated cell-cycle progression in cancer cells, but it is still a potent anticancer medicine and must be used under close specialist supervision with regular monitoring.

Q3: How long will I need to stay on palbociclib treatment?
Many patients remain on palbociclib-based therapy for as long as it continues to control the disease and side effects remain manageable. The optimal duration varies between individuals and depends on response, tolerability and the availability of alternative options. Only your oncology team can decide how long you should continue Palbocib 125 mg.

Q4: Can I miss or delay a dose of Palbocib 125 mg?
If you miss a dose or vomit after taking a capsule, you should follow the instructions from your oncologist or patient leaflet. In general, you should not double your next dose to make up for one that was missed. Any questions about missed doses or delays should be discussed with your care team, who may adjust your schedule if needed.

Q5: Do I need special blood tests while on Palbocib 125 mg?
Yes. Regular blood tests are an essential part of palbociclib therapy, especially to monitor white blood cell and neutrophil counts, platelets and liver function. These tests help your team decide whether it is safe to start a new cycle, whether dose adjustments are needed and how to manage any side effects that arise.

Indenza Enzalutamide – 40 mg (1 pack / 112 capsules)

At a Glance

Brand name: Indenza

Generic name: Enzalutamide

Active ingredient: Enzalutamide

Strength & pack size: Indenza 40 mg (1 pack / 112 capsules)

Dosage form: Oral hard capsules

Main indication: Advanced and metastatic castration-resistant prostate cancer and other androgen-driven settings as indicated

Therapeutic class: Androgen receptor inhibitor (hormonal anticancer therapy)

Use in therapy: Systemic oral treatment alongside ongoing androgen deprivation therapy (ADT)

Prescription status: Prescription-only anticancer medicine

Supplied by: Licensed manufacturers and authorised distributors

Storage: Store below 25 °C in a dry place, protected from moisture and light

Product Description

Indenza 40 mg capsules are a generic enzalutamide medicine used in the treatment of advanced and metastatic
prostate cancer. Enzalutamide is a potent oral androgen receptor inhibitor that blocks androgen-driven signalling
inside prostate cancer cells. Indenza 40 mg (1 pack / 112 capsules) provides a larger monthly supply of
enzalutamide 40 mg capsules that can match your specialist’s written treatment plan.

In many protocols, enzalutamide is used for metastatic castration-resistant prostate cancer (mCRPC) and in other settings such as
metastatic castration-sensitive or non-metastatic castration-resistant disease, according to recognised guidelines.
Because Indenza is a generic enzalutamide product, it contains the same active ingredient as branded enzalutamide while offering more accessible pricing in USD
for long-term hormonal therapy.

A typical adult daily dose is 160 mg, often given as four Indenza 40 mg capsules once daily, although your oncology or urology team may adjust this.
The pack of Indenza 40 mg (1 pack / 112 capsules) usually corresponds to a 28-day supply at 160 mg per day.
Treatment with Indenza enzalutamide is usually combined with continuous androgen deprivation therapy (ADT) using LHRH analogues or after surgical castration.

When you buy Indenza 40 mg online from Generic Meds Mart, you receive generic enzalutamide capsules supplied by licensed manufacturers and authorised distributors
that comply with recognised GMP standards. Discreet outer packaging protects your privacy, while original blisters and cartons preserve all product details such as strength, batch number and expiry date.

This Indenza 40 mg enzalutamide product is intended only for patients under specialist oncology or urology care.
Generic Meds Mart does not diagnose cancer or alter treatment plans; the information here supports informed discussions with your treating team about access to
generic enzalutamide capsules.

Key Uses

Indenza 40 mg enzalutamide capsules are generally used for the following indications under specialist supervision:

• Treatment of metastatic castration-resistant prostate cancer (mCRPC) alongside continuous androgen deprivation therapy
• Treatment of metastatic castration-sensitive or non-metastatic castration-resistant prostate cancer in selected patients according to recognised guidelines
• Continuation or switch therapy in men previously treated with other hormonal agents or chemotherapy when an androgen receptor inhibitor is recommended

Your specialist will determine whether Indenza 40 mg is appropriate, how it fits into your overall treatment plan and how long
enzalutamide therapy should continue.

How Enzalutamide Works in Chemotherapy

Enzalutamide is an oral hormonal anticancer agent often grouped within modern systemic chemotherapy and targeted hormonal regimens.
Indenza 40 mg contains enzalutamide, an androgen receptor inhibitor that blocks androgen-driven signalling in
prostate cancer cells.

In androgen-dependent prostate cancer, hormones such as testosterone and dihydrotestosterone bind to androgen receptors, which then move into the cell nucleus and activate genes that promote tumour growth and survival.
Indenza enzalutamide capsules act at several stages of this process: they bind to the androgen receptor with high affinity, prevent androgen binding, reduce nuclear translocation and limit DNA binding and gene activation.
By disrupting androgen receptor signalling, Indenza 40 mg can slow tumour growth, lower PSA levels and delay complications of advanced prostate cancer.

Although more targeted than many traditional cytotoxic agents, enzalutamide still has systemic effects and can influence the nervous system, blood pressure and liver function.
Careful monitoring by an experienced oncologist or urologist is therefore essential during Indenza enzalutamide therapy.

Dosage & Administration

Indenza 40 mg enzalutamide capsules must always be taken exactly as prescribed by your specialist.
Daily dosing, treatment duration and any dose changes depend on your diagnosis, other medicines and how you tolerate therapy.

• Take Indenza capsules by mouth once daily, with or without food, at approximately the same time each day.
• Swallow Indenza 40 mg capsules whole with water; do not open, crush or chew them unless your doctor or pharmacist gives specific instructions.
• Continue concurrent androgen deprivation therapy (ADT) unless your doctor has already performed surgical castration and advised otherwise.
• Do not change your dose, skip doses or stop taking Indenza without clear guidance from your oncology or urology team.
• If you miss a dose, follow your doctor’s instructions; do not take extra capsules to compensate unless specifically advised.

Your specialist will schedule regular visits, PSA tests, blood pressure checks and other investigations to monitor your response to
Indenza enzalutamide and to adjust treatment as needed.

Precautions

Before starting Indenza 40 mg, inform your doctor about your full medical history and all medicines, supplements and herbal products you use. Important considerations include:

• History of seizures, epilepsy, brain injury, stroke or conditions that increase seizure risk
• Cardiovascular disease, high blood pressure, heart failure or rhythm disturbances
• Pre-existing liver impairment or significant hepatic disease
• Previous falls, fractures or conditions affecting bone strength or balance
• Use of strong CYP2C8 or CYP3A4 inhibitors or inducers and medicines with a narrow therapeutic index
• Use of over-the-counter products or herbal remedies that may interact with enzalutamide

Enzalutamide is not intended for use in women and may harm an unborn baby. Men taking Indenza 40 mg are usually advised to use effective contraception if their partner may become pregnant, both during treatment and for a period afterwards, as directed by their doctor.

Enzalutamide Side Effects

Common side effects

Many patients experience side effects when starting Indenza enzalutamide capsules, especially during the first months of therapy. Common reactions may include:

• Fatigue, low energy or general tiredness
• Hot flushes
• Increased blood pressure or worsening of existing hypertension
• Headache, dizziness or difficulty concentrating
• Back pain, joint pain or muscle discomfort
• Mild swelling of the hands, ankles or feet
• Mild diarrhea, nausea or reduced appetite

These side effects are often manageable with supportive care or adjustments in overall management, but you should report persistent or troublesome symptoms to your oncology team.

Serious side effects

Some side effects of enzalutamide are less common but serious and require urgent medical attention. Serious reactions may include:

• Seizures, sudden loss of consciousness or unusual movements
• Severe confusion, strong headache or visual changes
• Very high blood pressure, chest pain or shortness of breath suggesting a cardiovascular event
• Signs of severe liver problems, such as yellowing of the skin or eyes, dark urine, pale stools or intense upper abdominal pain
• Repeated falls, new fractures or sudden severe bone pain

If you experience any of these serious symptoms while taking Indenza 40 mg, seek immediate medical care and contact your specialist as soon as possible.

Storage

• Store Indenza 40 mg capsules at room temperature, usually below 25 °C, in a dry place away from direct sunlight and excess heat.
• Keep the capsules in their original blisters and carton until use to protect them from moisture and light.
• Keep enzalutamide capsules out of the sight and reach of children and pets.
• Do not use the medicine after the expiry date printed on the packaging.

Ask your pharmacist or follow local regulations for safe disposal of unused or expired Indenza enzalutamide capsules.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on providing reliable access to essential oncology medicines such as
Indenza 40 mg enzalutamide capsules at fair prices in USD.
We work only with licensed manufacturers and authorised distributors that comply with recognised GMP standards and maintain a documented export track record.

When you buy Indenza 40 mg online from Generic Meds Mart, you benefit from:

• Competitive pricing on generic enzalutamide capsules compared with many local pharmacies
• Discreet, plain packaging designed to protect your privacy during shipping
• Tracked international delivery options to many destinations
• Clear, structured product information to support discussions with your oncologist or urologist
• Customer support available to assist with ordering, payment and shipping questions

Our goal is to help you maintain continuity of prescribed hormonal therapy with transparent conditions and professional handling of each order.

Order Now

Indenza 40 mg enzalutamide capsules are prescription-only anticancer medicines and must be used strictly under the supervision of an experienced oncologist or urologist.
Before you order Indenza 40 mg online, ensure that you have a valid prescription or written treatment plan specifying enzalutamide, the daily dose and the intended duration of therapy.

Select Indenza 40 mg (1 pack / 112 capsules), choose the appropriate quantity, add Indenza to your cart and complete the secure checkout process.
Your order will be processed, packed discreetly and shipped with tracking where available.

Generic Meds Mart does not provide diagnosis or personalised medical advice. All treatment decisions, dose changes and monitoring remain the responsibility of your healthcare team.